Core Viewpoint - The article highlights the approval of the PulsedFA® FocalPoint catheter by the National Medical Products Administration (NMPA) in China, marking a significant advancement in the treatment of paroxysmal supraventricular tachycardia and expanding the product line of Sichuan Jinjiang Electronic Medical Equipment Technology Co., Ltd. [1][2][4] Product Overview - The PulsedFA® FocalPoint catheter is designed for cardiac pulsed field ablation (PFA) and is used in conjunction with the company's cardiac pulsed ablation system. It features an innovative design that allows for precise application of high-voltage pulse energy to target tissues, enhancing surgical efficiency and reducing complications such as cardiac perforation [4][6]. - This is the second PFA catheter developed by the company, following the first PulsedFA® catheter, and it is part of the NMPA's green channel for innovative products, indicating its importance in the rapid arrhythmia treatment market [4][6]. Market Potential - The market for PFA in China is projected to reach 1.3 billion yuan by 2025, with a compound annual growth rate (CAGR) of 43.73%, expected to grow to 16.3 billion yuan by 2032. The PFA market's share of the overall electrophysiology device market is anticipated to increase from 8.18% in 2025 to 38.87% in 2032 [8]. Clinical Research - A clinical trial led by the electrophysiology team at West China Hospital evaluated the safety and feasibility of the PulsedFA® FocalPoint catheter in patients with atrioventricular nodal reentrant tachycardia (AVNRT). The study reported a 100% acute ablation success rate, with all patients maintaining sinus rhythm at the six-month follow-up without any adverse events [14][18][22]. Company Background - Sichuan Jinjiang Electronic was established in 2002 and is one of the few companies in China with a complete line of cardiac electrophysiology products. The company focuses on developing a three-dimensional PFA treatment solution and offers a range of products including mapping systems, ablation devices, and related consumables [24][28]. - The company has successfully raised over 700 million yuan in financing from notable investors and submitted an IPO application to the Sci-Tech Innovation Board to raise 2.691 billion yuan [28].

字MedTech 全球最新医疗科技动态 变局时代企业家思维破茧 全面打通产学研用 解锁医疗产业未来 成就卓越领军人才 我们面临的问题无比复杂, 您需要站在更高的平台, 洞祭趋势,明确方向,做出取舍, 分合行动,聚拢资源, 成为医疗产业未来的合格舵手! 00 0 0 00 /0 N7/2 | THE 课程价值 上海交通大学医学院拥有: 日 13家附属医院 R 21位院士 转化医学国家重大科技基础设施(上海) 为企业家提供了强大的学术支持、创新平台 和临床转化资源 独创价值引擎方法论 以"用"为牵引，产学研用协同, 构建企业家思维方法体系, 锤炼具备战略眼光、创新能力 和领导力的复合型人才。 ： 思宇MedTech | MedRobot | 心未来 | 眼未来 | 骨未来 | 探美医界 | 医影像 寻求报道，请联系Alice：suribot21 投稿/订制报告，请联系主编： qingzhao2017 SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE 第十期 MEDICAL AND HEALTH FUTURE LEADING TALENTS 300位 多目 8 TE ...

首届全球骨科大会 Global Orthopedics Conference 2025 一、大会时间： 2025年4月24日 星期四 9:00-17:30 二、大会地点： 北京市中关村自主创新示范区展示中心（海淀桥西北角） 三、举办单位： 骨未来｜智汇骨 | 思宇MedTech；中关村联新生物医药产业联盟、北京中关村科学城创新发展 有限公司、北京中关村创业大街科技服务有限公司、启迪之星、 中关村科学城CGT产业孵化中心 四、大会福利：15万字骨科年度报告+政府闭门对接会+ 创新产品展区 （医生参会者，可私信后台获得免费票优惠码，可打印附件邀请函 https://kdocs.cn/l/coDZpG1Vftnv ） # 转发赠票（含资料），方法附文末 五、大会议程 | 时间 | 内容 | | --- | --- | | 9:00-9:05 | 致辞环节 | | | 林航，海淀区副区长 | | | 吴新宝，北京积水潭医院副院长 | | 9:05-9:08 | 《2025 全球骨科创新年度白皮书和数据发布》 | | 9:08-9:15 | 全球骨科器械创新大奖颁布 | 9:15-9:30 《北京市生物医药产业环境与政 ...

一次创新思维的碰撞，一场探索医疗科技创新的合作之旅！ 医生 ×CEO ×工程师 ×投资人 强强联合，破解医疗器械创新难题！ 如果你对 医疗器械创新、医工结合、技术转化 充满兴趣，那么这次 上海交通大学医学院 × 附属医院 × 生物医学工程学院 联合打造的 「医疗器械医工创新转化工作 坊」 ，就是你的绝佳机会！ 课程亮点 你将获得 培训信息 时间： 2025年6月（周末2天，具体时间提前一个月通知） 地点： 上海交通大学医学院 费用： 8999元/人（含课程、教材、茶点等，食宿自理） 主办单位： 上海交通大学医学院继续教育学院 支持 单位： 中关村联新生物医药产业联盟 第一天：医疗创新与技术布局 晚上：技术解决方案对接会 第二天：创新产业化与资金路径 医工创新产业的关键点及资金来源 课程安排 课程安排 | 2天高强度实战训练，全面掌握医工创新转化 让医学痛点与工程技术深度融合，打造医疗创新产品，助力成果转化！ 是否曾有一个医疗创新的想法，却不知如何落地？ 是否苦于医生与工程技术团队难以有效协作？ 是否希望掌握医疗器械从概念到市场的完整路径？ Biodesign 医工创新方法论： 全球前沿医工创新模式，助力高效转 ...

近日，思宇MedTech注意到波士顿科学的一则招聘信息：房颤解决方案事业部启动"百岗校招"计划， 面向2025届应届生及毕业两年内的候选人，开放150 个临床技术培训生岗位，覆盖全国34个省市。 与以往偏向市场、销售类岗位的招聘不同，此次的重点落在了被业内称为"跟台岗"的 临床一线技术支持人员 。根据招聘描述，新入职者将直接参与房颤治 疗手术全过程，包括术前准备、术中支持及术后沟通。换句话说，他们从培训结束后就能站上手术现场，服务于真实病例和真实操作。 这看上去不仅是一轮简单的人才扩充，更是波士顿科学在中国房颤市场加速深化临床部署、全面提升一线渗透力的重要举措。 2024年，波士顿科学的 FARAPULSE脉冲电场消融系统 获得国家药品监督管理局（NMPA）批准，成为国内首款进口PFA系统。同时，其在房颤卒中预防 方向上的代表产品—— Watchman左心耳封堵系统 ——也在中国进入成熟应用期。 在思宇看来，这场校招，是波士顿科学"重投临床、深耕一线"战略思路的具体体现。通过年轻技术人才的广泛铺设，波士顿科学或将打通产品—术式—医院 —医生之间的落地通路，为房颤整体解决方案在中国的本地化放量奠定基础。 一、房 ...

近日，思宇MedTech注意到波士顿科学的一则招聘信息：房颤解决方案事业部启动"百岗校招"计划， 面向2025届应届生及毕业两年内的候选人，开放150 个临床技术培训生岗位，覆盖全国34个省市。 与以往偏向市场、销售类岗位的招聘不同，此次的重点落在了被业内称为"跟台岗"的 临床一线技术支持人员 。根据招聘描述，新入职者将直接参与房颤治 疗手术全过程，包括术前准备、术中支持及术后沟通。换句话说，他们从培训结束后就能站上手术现场，服务于真实病例和真实操作。 这看上去不仅是一轮简单的人才扩充，更是波士顿科学在中国房颤市场加速深化临床部署、全面提升一线渗透力的重要举措。 2024年，波士顿科学的 FARAPULSE脉冲电场消融系统 获得国家药品监督管理局（NMPA）批准，成为国内首款进口PFA系统。同时，其在房颤卒中预防 方向上的代表产品—— Watchman左心耳封堵系统 ——也在中国进入成熟应用期。 在思宇看来，这场校招，是波士顿科学"重投临床、深耕一线"战略思路的具体体现。通过年轻技术人才的广泛铺设，波士顿科学或将打通产品—术式—医院 —医生之间的落地通路，为房颤整体解决方案在中国的本地化放量奠定基础。 一、房 ...

Core Viewpoint - Adagio Medical's vCLAS cryoablation system has received FDA breakthrough device designation, marking a significant regulatory milestone in the treatment of ventricular tachycardia (VT) [2][4][5] Group 1: vCLAS System Overview - The vCLAS system is designed to treat drug-resistant, recurrent, and persistent monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease [4][5] - It utilizes Adagio's proprietary ultra-low temperature cryoablation (ULTC) technology, which can create deeper and more durable lesions compared to traditional methods, potentially improving the safety and efficacy of VT ablation procedures [4][5][12] - The system consists of a cryoablation console and a vCLAS ablation catheter, which features a 15cm long distal ablation segment with eight 1mm electrodes for intracardiac electrogram recording and identification [7][9] Group 2: Market and Treatment Landscape - The incidence of VT varies among populations and is associated with various factors, including coronary artery disease and certain hereditary heart disease syndromes [6] - The VT treatment market has been growing rapidly, with traditional methods like drug therapy and radiofrequency ablation facing limitations in effectiveness and safety [6] - There is increasing demand for cryoablation technology, which offers advantages such as minimal trauma and quick recovery, leading to an expanding market size in the coming years [6] Group 3: Technological Innovations - Adagio Medical has developed unique technologies such as near-critical nitrogen (NCN) cryoablation, which addresses issues like liquid nitrogen volume expansion and allows for precise control of the ablation range and depth [13][16] - The ultra-low temperature cryoablation (ULTC) technology enables the creation of extensive and continuous lesions in both atria and ventricles during a single ablation cycle [17][19] - The pulse field cryoablation (PFCA) technology combines ULTC and pulse field ablation (PFA) in a single catheter, potentially revolutionizing cardiac treatment by preventing bubble formation and allowing for higher voltage operations [20][23] Group 4: Company Background - Adagio Medical, founded in 2011 and headquartered in California, focuses on developing and commercializing products for arrhythmia treatment using its proprietary ultra-low temperature cryoablation technology [35][36] - The company's product line includes the iCLAS system for atrial fibrillation and the vCLAS system for VT, with ongoing clinical trials and regulatory approvals in Europe and the U.S. [36]

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月10日，总部位于 苏格兰 的Neuranics公司获得了800万美元（合约5800万人民币）的种子资金，以加快其隧道磁阻（TMR）磁感应技术的增长 和商业应用。 本轮融资由Blackfinch Ventures领投，Archangels参与投资，并得到了格拉斯哥大学、Par Equity和爱丁堡大学的风险投资基金Old College Capital的支 持。 资金将用于公司下一阶段的发展，包括加强团队建设、技术创新以及将TMR技术整合到各种高科技市场，特别是在可穿戴设备、扩展现实（XR）和数字健康 领域。 # 核心技术 技术背景 隧道磁阻（TMR） 是一种量子物理现象，指的是在特定的磁性结构中，电阻值会随着磁化方向的变化而发生显著变化，在磁性隧道结（MTJ）中尤为明显。 由于TMR效应导致的电阻变化与磁场强度、方向密切相关，因此可以通过测量电阻的变化来精确检测磁场的特性。 从左到右依次为 CTO Hadi Heidari、CEO Noel McKenna、CSO Kia Na ...

Core Viewpoint - Neuranics has secured $8 million in seed funding to accelerate the growth and commercial application of its Tunneling Magnetoresistance (TMR) technology, which is expected to enhance various high-tech markets, particularly in wearable devices, extended reality (XR), and digital health [2][6]. Group 1: Technology Background - Tunneling Magnetoresistance (TMR) is a quantum physical phenomenon where the resistance in specific magnetic structures changes significantly with the direction of magnetization, allowing for precise magnetic field detection through resistance measurement [3]. Group 2: Technology Features - Neuranics has developed ultra-sensitive magnetic sensors based on TMR technology that can non-invasively capture weak magnetic signals from the human body, such as muscle activity and heart signals, offering higher accuracy, lower power consumption, and continuous monitoring capabilities compared to traditional methods [6]. Group 3: Future Applications - Potential applications of TMR sensors include: - Biomedical field: Detecting weak magnetic fields from the heart (Magnetocardiography, MCG) and brain (Magnetoencephalography, MEG) [8]. - Wearable devices: Monitoring muscle activity and gesture recognition without direct skin contact, enhancing user comfort and device practicality [9]. - Extended reality (XR): Tracking user head and hand positions for a more immersive experience in virtual and augmented reality [9]. Group 4: Recent Developments - Neuranics received £800,000 in funding from Scottish Enterprise to support a research project aimed at transforming human-machine interaction through innovative wristband technology [9]. - The company established an advanced magnetic laboratory at the University of Glasgow to expand its R&D capabilities, focusing on non-contact muscle activity monitoring and continuous magnetic heart monitoring [14][15]. Group 5: Company Overview - Neuranics, founded in 2021, is a joint incubation company from the University of Glasgow and the University of Edinburgh, recognized with global technology awards such as the CES Innovation Award [16]. - The leadership team includes: - CEO Noel McKenna, with over 30 years of experience in the international electronics industry [17]. - CSO Kia Nazarpour, a professor in digital health at the University of Edinburgh [19]. - CTO Hadi Heidari, a professor at the University of Glasgow specializing in microelectronics and biomedical sensors [20].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 近日， 高视医疗 （02407.HK）全资附属公司北京高视远望科技有限责任公司所代理的德国 海德堡 （ Heidelberg）公司出品的 ANTERION 眼科检测仪（三合一眼前节多模影像诊断平台） 获得中国药监局 医疗器械注册证 ，该仪器集多项功能于一体，能提升眼科诊疗效率，丰富集团产品组合。 该产品自2024年起在美国上市，是一款 集生物测量仪、角膜地形图、前节OCT于一体 的多模影像诊断平 台，能够在屈光、角膜病、青光眼、视光等多个眼科亚专科领域发挥重要作用。在屈光手术中， ANTERION眼科检测仪能精准评估角膜上皮厚度和视觉质量，引导个性化切削 方案；在白内障手术中，结 合角膜地形图与生物测量数据，可降低术后屈光意外风险。 ANTERION 眼科检测仪运用 1300nm 波长的 SS-OCT 技术 ，具有穿透力强、扫描速度快、成像分辨率高 的特点，结合 动眼追踪（Eye-tracking）和光线追踪（Ray-tracing）技术 ，提供高效全面的眼前节诊 疗解决方案，一台设备即可完 ...